Identifying the Anti-Blood-Clotting Compounds in Garlic - Full Text View

Sponsored by:	National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by:	National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:	NCT00200785

Purpose

This study will seek to identify the compound(s) in garlic that are responsible for its ability to prevent the formation of blood clots and to determine the maximally effective dose and the duration of the benefits. This study will also determine whether cooked garlic is as effective as fresh garlic and, if more than one compound is involved, and whether their combined effects are more significant than the effects of each compound alone.

Condition	Intervention
Arteriosclerosis Intracranial Arteriosclerosis	Drug: garlic: fresh, cooked, extracts

Drug Information available for: Allium sativum extract

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Identification of the Antiplatelet Compounds of Garlic Ex Vivo

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Primary Outcome Measures:

cardiovascular disease
cerebrovascular disease

Estimated Enrollment:	10
Study Start Date:	October 2004
Study Completion Date:	September 2007

Detailed Description:

Studies indicate that various types of undefined garlic products display antiplatelet activity. However, the compounds responsible for this antiplatelet effect have not been identified.

Participants will consume several doses of fresh garlic in a sandwich. At 0, 2, 4, and 6 hours after consumption, the ability of platelets, as drawn whole blood, to aggregate in response to a drug that stimulate platelet agonist (collagen, ADP) will be measured by electrical impedance.

After establishing the optimum dose and optimum time of the antiplatelet effect for each person, the effects of cooked garlic and seven extracted fractions (oil, protein, fructans, etc.) will be determined, using the fractions at the same dose as their abundance in the established optimum dose of crushed fresh garlic.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Body mass index of 42 to 66 lbs/m2
Plans to remain in the study area for the next year
Willingness to abstain from nonsteroidal anti-inflammatory drugs (NSAID drugs for 1 week prior to each study test
Willingness to abstain from consuming garlic and significant amounts of onion, chocolate, or purple grape juice for 3 days prior to each study test
Willingness to participate in all study tests

Exclusion Criteria:

Pregnancy or breast-feeding
Serious medical condition
Allergy to garlic or wheat
Tobacco use
Excessive alcohol consumption
Under psychiatric care

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00200785

Locations

United States, Utah
Plant Bioactives Research Institute
Orem, Utah, United States, 84058

Sponsors and Collaborators

National Center for Complementary and Alternative Medicine (NCCAM)

Investigators

Principal Investigator:

Larry D. Lawson, PhD

Plant Bioactives Research Institute

More Information

Study ID Numbers:	R21 AT001512-01
Study First Received:	September 12, 2005
Last Updated:	September 28, 2007
ClinicalTrials.gov Identifier:	NCT00200785
Health Authority:	United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):

garlic

Study placed in the following topic categories:

Arterial Occlusive Diseases
Intracranial Arteriosclerosis
Vascular Diseases
Central Nervous System Diseases

Arteriosclerosis
Brain Diseases
Cerebrovascular Disorders
Intracranial Arterial Diseases

Additional relevant MeSH terms:

Nervous System Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009